1. Balog, Steven, Fujiwara, Reika, Pan, Stephanie Q, Ng, Stanley W-K, Tsukamoto, Hidekazu. 2022. Emergence of highly profibrotic and proinflammatory Lrat+Fbln2+ HSC subpopulation in alcoholic hepatitis. In Hepatology (Baltimore, Md.), 78, 212-224. doi:10.1002/hep.32793. https://pubmed.ncbi.nlm.nih.gov/36181700/
2. Niu, Xiaomin, Zhang, Fuyu, Gu, Wei, Zhang, Bo, Chen, Xiaowei. 2024. FBLN2 is associated with Goldenhar syndrome and is essential for cranial neural crest cell development. In Annals of the New York Academy of Sciences, 1537, 113-128. doi:10.1111/nyas.15183. https://pubmed.ncbi.nlm.nih.gov/38970771/
3. Welch, Carrie L, Aldred, Micheala A, Balachandar, Srimmitha, Tenorio-Castano, Jair, Chung, Wendy K. 2023. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension. In Genetics in medicine : official journal of the American College of Medical Genetics, 25, 100925. doi:10.1016/j.gim.2023.100925. https://pubmed.ncbi.nlm.nih.gov/37422716/
4. Li, Wei-Ming, Chan, Ti-Chun, Huang, Steven Kuan-Hua, Shiue, Yow-Ling, Li, Chien-Feng. 2020. Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma. In Frontiers in oncology, 10, 570340. doi:10.3389/fonc.2020.570340. https://pubmed.ncbi.nlm.nih.gov/33194662/